At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Cambridge based Director operating in the Life Science space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Joshua Resnick
Managing Director of RA Capital Management
Josh is co-founder and chief executive officer of Ataxion, and previously served on the board of CoStim Pharmaceuticals, which was sold to Novartis in February 2014. He is also an attending physician in emergency medicine at Brigham and Women’s Hospital as well as an instructor at Harvard Medical School. Prior to joining Atlas, Josh was a partner at Prism Ventures.
Follow Joshua Resnick:
About Caraway Therapeutics, RA Capital Management: RA Capital Management is an investment advisor specializing in the life-sciences and drug development sectors.
Ray Edgson
Director of evonetix
Follow Ray Edgson:
About evonetix: Evonetix is a provider of a desktop platform designed to synthesize DNA at unprecedented accuracy and scale.
Andreas Bender
Non Executive Director of PharmEnable
Andreas Bender is a Lecturer for Molecular Informatics with the Centre for Molecular Informatics at the University of Cambridge. Until April 2010 he was an Assistant Professor for Cheminformatics and Pharmaceutical IT with the Leiden / Amsterdam Center for Drug Research and Head of the Pharma-IT Platform at Leiden University. In his work, he is involved with the analysis of various kinds of bioactivity data and the generation of property prediction models, mainly for small molecules.
Follow Andreas Bender:
About NUVISAN GmbH, PharmEnable, University of Cambridge: PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery.
Eric Boutin
Managing Director of dRx Capital
Eric Boutin was Founder | CEO of Evolve, acquired by HubSpot (NYSE: HUBS). He was Founder | CEO of Good Start Genetics, acquired by Invitae (NYSE: NVTA). He was Founder | VP of Flex Pharma, IPO (NASDAQ: FLKS). Eric was an EIR at Longwood Fund, and Founder of HBS Angels Boston. He holds a BA from Duke University, and an MBA from Harvard.
Follow Eric Boutin:
About dRx Capital: Novartis Digital Health Venture Capital
Magdeline Pokar
Founder, Managing Director of Asia Research News
Maggie is the managing director of Asia Research News, overseeing all aspects of this innovative startup.
Follow Magdeline Pokar:
About Asia Research News: Asia Research News connects researchers with international media, policy makers, fellow collaborators and the science-hungry public.
Dan Cowell
Non Executive Director of Sentinel Oncology
Dan has over 15 years’ experience in the contract research and biotechnology industries. He has been involved in ‘hit to lead’ discovery and the investigation of new technologies in the areas of automation, high-throughput catalysis, pharmaceutical solid form and lead generation. Dan was co-founder of Pharmorphix, a specialist CRO in the area of solid form, which grew market share rapidly and was subsequently acquired by Sigma Aldrich in 2006. Following the sale of Pharmorphix he founded Hypoxium, a client focused CRO providing pre-clinical oncology research which grew its revenue at over 75% each year. He was appointed COO of Horizon Discovery following its acquisition in 2010.
Follow Dan Cowell:
About Sentinel Oncology: Sentinel Oncology is a drug discovery company specialising in the delivery of candidate drugs to treat diseases.
Niall Lennon
Senior Director and Translational Genomics of Broad Institute
Follow Niall Lennon:
About Broad Institute, Tufts University: The Broad Institute brings together a diverse group of individuals from across its partner institutions to confront biomedical challenges.
Anne Carpenter
Institute Scientist and Imaging Platform Senior Director of Broad Institute
Follow Anne Carpenter:
About Broad Institute: The Broad Institute brings together a diverse group of individuals from across its partner institutions to confront biomedical challenges.
Noel Burtt
Associate Director, Operations, Daibetes Research and Knowledge Portals of Broad Institute
Follow Noel Burtt:
About Broad Institute, Broad Institute: The Broad Institute brings together a diverse group of individuals from across its partner institutions to confront biomedical challenges.
Jiahao Huang
Co-founder, Director and CFO of Nuclera
A molecular biologist by trade, Jiahao has coordinated multi-national collaborative projects and experienced first hand the limitations of the current provision of DNA. This intimate knowledge of user requirements enables him to guide Nuclera’s commercial operations towards creating the right product for the right market. Jiahao holds a BSc from the University of California, Berkeley, and a PhD in Molecular Biology from the University of Cambridge.
Follow Jiahao Huang:
About Nuclera: Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.
Olga Granaturova
Co-Founder, COO, and Director of Parthenon Therapeutics
Olga Granaturova is the Co-Founder, COO, and Director at Parthenon Therapeutics.
Follow Olga Granaturova:
About Parthenon Therapeutics: Parthenon Therapeutics is a biotech company inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment.
Andrew Southan
Chief Executive and Executive Director of Metrion Biosciences
Andy has over 25 years’ experience in life science research, including 14 years in the CRO sector. In 1991 he received his PhD in Pharmacology from the University of London (UK), investigating the effects of anaesthetics and high pressure on CNS potassium channels. Following a move to industry Andy worked as a brain slice electrophysiologist supporting ion channel-based CNS programmes at Wyeth (UK), before moving to Imperial College London where he published the first patch-clamp recordings from cerebellar inhibitory nerve terminals. At CeNeS Pharmaceuticals he performed CRO services (hERG, nAChR) and internal research on HCN and two-pore channels. He subsequently established the electrophysiology laboratory for Ionix Pharmaceuticals, a company focused on identifying novel pain therapeutics, where he worked on Nav, Cav and mechanosenstive ion channels. Before joining Metrion Andy spent 12 years in leadership roles at BioFocus and Charles River managing stand-alone projects, multi-year collaborations and fully integrated drug discovery programmes.
Follow Andrew Southan:
About Metrion Biosciences: Metrion Biosciences is a Contract Research Organization (CRO) that is located in the world renowned Cambridge biocluster.
Richard Saumarez
Director of Fen EP Limited
Follow Richard Saumarez:
About Fen EP Limited: Fen EP Limited is a developer of biomedical device created to prevent sudden cardiac death.
Richard Saumarez
Director of Fen EP Limited
Follow Richard Saumarez:
About Fen EP Limited: Fen EP Limited is a developer of biomedical device created to prevent sudden cardiac death.